G4_Eubacterium_rectale_DMSO_30_vs_G3_Eubacterium_rectale_Duloxetine_47

Profile details

Identifier: MTBLS1792_0001_00000018
Linked study: MTBLS1792 — Bioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)
Comparison: Eubacterium rectale_DMSO_30 vs Eubacterium rectale_Duloxetine_47
Group A: Eubacterium rectale treated with 30 micromolar DMSO. Serves as a baseline to compare the effects of duloxetine.
Group B: Eubacterium rectale treated with 47 micromolar duloxetine. Helps in understanding the effect of duloxetine at the highest concentration.
Total features tested: 2786
Significant features: 29
p-value threshold: 0.05
Ratio threshold (upper): 1.5
Ratio threshold (lower): 1/1.5
Date created: 2025-09-26 00:00:00

Metabolite ID (InChI Key)	Name	Direction	Ratio	p-value
UCSJYZPVAKXKNQ-HZYVHMACSA-N	streomycin	up	1e+06	0.0102
YUXKTUVIOWXKPA-UHFFFAOYSA-N	—	up	1e+06	0.0493
MIDRXTGJGROJRO-JFXDCXPESA-N	N-[(2R,3S,4R)-4-hydroxy-2-(hydroxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-yl]acetamide	up	1e+06	0.0494
SXLFMZWGFIBWMJ-QTGWYDPFSA-N	N-[(2R,3S,4R)-3-hydroxy-2-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-yl]acetamide	up	1e+06	0.0494
ZFHPYBQKHVEFHO-LECUDPRGSA-N	—	down	1e-06	0.0494
RJCPXHXLCWWGHO-APFRPCTBSA-N	—	down	1e-06	0.0494
XUKIKVBUXFVHNV-MFAQWRDPSA-N	—	down	1e-06	0.0494
RPHLHZIDWIFTII-RJQMMLODSA-N	(Z)-7-[(1S,2E)-5-[(2R)-2-[[(4R)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]sulanyl-2-[(3S)-3-hydroxyoctylidene]-3-oxocyclopentyl]hept-5-enoic acid	down	1e-06	0.0494
PSHXNVGSVNEJBD-LJQANCHMSA-N	(<i>R</i>)-myristoylcarnitine	down	1e-06	0.0495
FDGQSTZJBFJUBT-UHFFFAOYSA-N	Purine-6-ol	up	1e+06	0.0499